Biontech CEO Uğur Şahin
Photo: Andreas Arnold / dpa
The Mainz corona vaccine manufacturer Biontech is expanding.
An extensive job creation is planned for the coming months, the company said, according to a report by “Welt am Sonntag”.
500 new positions across all departments are currently advertised.
Before the corona pandemic, Biontech employed a good 1,300 people.
The company worked primarily on new therapies for cancer.
Together with the US company Pfizer, Biontech then developed the first vaccine against the coronavirus approved in many countries last year.
To do this, the company used the new mRNA technology, which is also used in the development of cancer immunotherapies.
In the past year and a half, the number of Biontech employees has increased to around 2000.
According to the report by “Welt am Sonntag”, the manufacturer now wants to invest in its own sales team of 60 employees for the first time in order to promote the marketing of approved products itself.
»We set up Biontech as a fully integrated company right from the start.
With its own research and development, production and now also a sales department, «said board member Sierk Poetting of the newspaper.
Biontech recently announced that it would also develop a vaccine against malaria based on its mRNA technology.
Since the corona vaccine »Comirnaty« also no longer protects those vaccinated against the new Delta mutant as well as against previous virus variants, the company is now preparing a vaccine specifically adapted to Delta.
kry / AFP